File(s) under permanent embargo
Fingolimod after natalizumab and the risk of short-term relapse
journal contributionposted on 2014-04-01, 00:00 authored by V G Jokubaitis, V Li, T Kalincik, G Izquierdo, S Hodgkinson, R Alroughani, J Lechner-Scott, A Lugaresi, P Duquette, M Girard, M Barnett, F Grand'Maison, M Trojano, M Slee, G Giuliani, Cameron ShawCameron Shaw, C Boz, D L A Spitaleri, F Verheul, D Liew
OBJECTIVE: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse on fingolimod. METHODS: Data were obtained from the MSBase Registry. Relapse rates (RRs) for each patient group were compared using adjusted negative binomial regression. Survival analyses coupled with adjusted Cox regression were used to model predictors of time to first relapse on fingolimod. RESULTS: A total of 536 patients (natalizumab-fingolimod [n = 89]; IFN-β/GA-fingolimod [n = 350]; naive-fingolimod [n = 97]) were followed up for a median 10 months. In the natalizumab-fingolimod group, there was a small increase in RR on fingolimod (annualized RR [ARR] 0.38) relative to natalizumab (ARR 0.26; p = 0.002). RRs were generally low across all patient groups in the first 9 months on fingolimod (RR 0.001-0.13). However, 30% of patients with disease activity on natalizumab relapsed within the first 6 months on fingolimod. Independent predictors of time to first relapse on fingolimod were the number of relapses in the prior 6 months (hazard ratio [HR] 1.59 per relapse; p = 0.002) and a gap in treatment of 2-4 months compared to no gap (HR 2.10; p = 0.041). CONCLUSIONS: RRs after switch to fingolimod were low in all patient groups. The strongest predictor of relapse on fingolimod was prior relapse activity. Based on our data, we recommend a maximum 2-month treatment gap for switches to fingolimod to decrease the hazard of relapse. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that RRs are not higher in patients with multiple sclerosis switching to fingolimod from natalizumab compared to those patients switching to fingolimod from other therapies.
Pagination1204 - 1211
Publication classificationC Journal article; C1.1 Refereed article in a scholarly journal
Copyright notice2014, American Academy of Neurology
AdultAntibodies, Monoclonal, HumanizedFemaleFingolimod HydrochlorideHumansImmunologic FactorsImmunosuppressive AgentsInterferon-betaMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingNatalizumabPropylene GlycolsRisk FactorsSecondary PreventionSphingosineTreatment OutcomeScience & TechnologyLife Sciences & BiomedicineClinical NeurologyNeurosciences & NeurologyREMITTING MULTIPLE-SCLEROSISORAL FINGOLIMODSWITCHING THERAPYMSINTERFERONEXTENSIONCESSATIONOUTCOMESFTY720MSBase Study Group